Roquefort Investments PLC (GB:ROQ) has released an update.
Roquefort Therapeutics PLC has announced the conversion of £267,106 worth of convertible loan notes into 6,586,604 new ordinary shares, as part of its strategy to bolster its presence in the immunology and oncology markets. This move, involving directors Stephen West, Ajan Reginald, and Darrin Disley, aligns with the company’s commitment to developing groundbreaking anti-cancer medicines. The newly issued shares will be admitted for trading on the London Stock Exchange, potentially impacting shareholder voting rights and interest notifications.
For further insights into GB:ROQ stock, check out TipRanks’ Stock Analysis page.
